학술논문
98LBA Late Breaking - Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 Gatipotuzumab (GAT) with the anti-EGFR Tomuzotuximab (TO) or Panitumumab in patients with refractory solid tumors
Document Type
Article
Author
Source
Subject
*PANITUMUMAB
*THERAPEUTIC use of monoclonal antibodies
*CONFERENCES & conventions
*TUMORS
*EPIDERMAL growth factor receptors
*
*
*
*
Language
ISSN
0959-8049